BALTIMORE,
Sept. 5,
2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc.
(NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage
pharmaceutical company focused on the development and
commercialization of a novel synthetic THC analog, today announced
its strategic partnership with MZ Group ("MZ"), a renowned
international investor relations firm.
This collaboration aims to enhance MIRA's
visibility within the investment community and spotlight the
potential of its drug candidate, MIRA1a, in treating anxiety,
cognitive decline, and neuropathic pain.
MIRA Pharmaceuticals dedicates itself to
addressing adult patients' treatment challenges with anxiety and
cognitive decline typically associated with anxiety disorders
including PTSD and Generalized Anxiety Disorder and early-stage
dementia. As part of its commitment to effective communication with
its stakeholders, MIRA has joined forces with MZ Group, leveraging
their expertise and global presence. MIRA aims to expand its
presence in key markets through a comprehensive investor relations
and financial communications program.
"Our collaboration with MZ Group underscores our
commitment to becoming a leader in neurological markets and the
expanding cannabis market," said Erez
Aminov, Chief Executive Officer of MIRA Pharmaceuticals.
"MZ's impressive track record and global network will help us reach
a broader audience, enabling us to convey the significant potential
of MIRA1a in treating neuropsychiatric, inflammatory, and
neurologic disorders."
MZ Group will leverage its global reach to
provide MIRA with invaluable insights and strategic guidance.
Michael Kim, Managing Director at MZ
North America, will advise MIRA Pharmaceuticals on corporate and
financial communications. This collaboration will include
coordinating roadshows and investment conferences and utilizing
various media platforms to amplify MIRA's brand visibility within
the investment landscape.
MIRA1a, in its pre-clinical and animal studies,
has demonstrated therapeutic benefits by targeting the cannabinoid
receptors CB1 and CB2. Unlike marijuana, MIRA1a offers these
benefits without the impurities and side effects commonly
associated with it, such as increased appetite, paranoia, and
cognitive impairment. The promising results obtained from
pre-clinical and animal studies indicate that MIRA1a may enhance
the treatment of anxiety, cognitive decline, and neuropathic
pain.
"Unprecedented among cannabinoid-related drugs is
MIRA1a's ability to double the performance of normal mice on tests
of memory and learning, which contrasts with THC's known
cognitively impairing effects," said Adam
Kaplin, MD, PhD, President and CSO of MIRA
Pharmaceuticals. "This demonstrates the potential of MIRA1a to
restore lost cognition to those with cognitive decline of diverse
etiologies."
"We are highly focused on the development of
MIRA1a, as we believe it holds immense potential to address the
significant unmet needs in the therapeutic landscape," added Mr.
Aminov. "MIRA's technology focuses on minimizing the negative
effects of THC and opening up new markets for indications and
patients. Our key candidate, MIRA1a, is being developed as the
first prescription drug to simultaneously target neuropathic pain,
anxiety and cognitive impairment while offering the ability to
achieve higher potency while maintaining safety and minimizing
side-effects. Our dedication to innovation and MZ Group's expertise
will enable us to effectively communicate our vision and create
long-term value for our shareholders."
About MZ Group
MZ Group is a globally recognized investor
relations firm providing comprehensive services tailored to meet
the unique needs of its clients. With offices worldwide, MZ Group
assists institutional investors, brokers, analysts, and private
investors in navigating the complex world of investor relations,
raising awareness, and facilitating connections between companies
and the investment community.
For more information, please
visit www.mzgroup.us.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a
pre-clinical-stage pharmaceutical development company developing an
unscheduled novel synthetic THC analog. This novel compound is
currently under investigation for treating adult patients suffering
from anxiety and cognitive decline, often associated with
early-stage dementia. MIRA1a, if approved by the FDA, could mark a
significant advancement in addressing various neuropsychiatric,
inflammatory, and neurologic diseases and disorders. Based on
pre-clinical and animal studies conducted by the Company, the
Company believes that MIRA1a may enhance the therapeutic potential
for treating anxiety, cognitive decline, and neuropathic pain
without the side effects of plant-based THC. Furthermore, the
Company's studies indicate that MIRA1a may counteract the adverse
cognitive effects often seen with THC, thereby potentially
unmasking previously unseen positive therapeutic effects, such as
cognitive performance enhancement.
The U.S. Drug Enforcement Administration (DEA)'s
scientific review of MIRA1a concluded that MIRA1a would not be
considered a controlled substance or listed chemical under the
Controlled Substances Act (CSA) and its governing regulations.
Additional information about the Company is
available at: www.mirapharmaceuticals.com.
Forward-Looking Statements
This press release contains forward-looking
statements regarding the Company's current expectations. These
forward-looking statements include, without limitation, references
to the Company's expectations regarding the closing of the public
offering and its anticipated use of net proceeds from the offering.
These statements are not guarantees of future performance and are
subject to certain risks, uncertainties and assumptions that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, risks and uncertainties
related to the satisfaction of customary closing conditions related
to the public offering, or factors that result in changes to the
Company's anticipated use of proceeds. These and other risks and
uncertainties are described more fully in the section captioned
"Risk Factors" in the Company's Registration Statement on Form S-1,
as amended, related to the public offering (SEC File No. File No.
333-273074). Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes
no duty to update such information except as required under
applicable law.
View original
content:https://www.prnewswire.com/news-releases/mira-pharmaceuticals-and-mz-group-partner-to-strengthen-investor-relations-and-shareholder-communication-efforts-301917248.html
SOURCE MIRA Pharmaceuticals, Inc.